Key statistics
On Friday, Novo Nordisk A/S (NVO:NYQ) closed at 102.63, 8.34% above its 52-week low of 94.73, set on Dec 11, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 103.18 |
---|---|
High | 103.22 |
Low | 101.51 |
Bid | 102.20 |
Offer | 103.50 |
Previous close | 105.27 |
Average volume | 5.93m |
---|---|
Shares outstanding | 3.39bn |
Free float | 2.11bn |
P/E (TTM) | 35.13 |
Market cap | 355.48bn USD |
EPS (TTM) | 3.00 USD |
Annual div (ADY) | 1.45 USD |
---|---|
Annual div yield (ADY) | 1.37% |
Div ex-date | Aug 16 2024 |
Div pay-date | Aug 26 2024 |
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
- Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
- Novo Nordisk A/S - share repurchase programme
- Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme
- Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024
- Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
- Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial
- Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
- Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities
- Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
More ▼